Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients

S. Ribero, S. Osella-Abate, M. Sanlorenzo, P. Savoia, C. Astrua, G. Cavaliere, C. Tomasini, R. Senetta, G. Macripò, M. G. Bernengo, P. Quaglino

Research output: Contribution to journalArticle

Abstract

Background The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma <1 mm. Objectives To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease-free survival (DFS) and overall survival (OS) in our series. Methods We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I-II melanoma. Results Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression in the primary. Using the Cox multivariate model, histological regression maintained a significant protective role [hazard ratio (HR) 0·62, P = 0·012 for DFS; HR 0·43, P = 0·008 for OS] when corrected for the principal histopathological and clinical features, despite SLNB. Conclusions We confirmed that regression alone should not be a reason to perform SLNB in thin melanoma and, on the contrary, it can be considered a favourable prognostic factor in patients with AJCC stage I-II melanoma. What's already known about this topic? Regression has been considered a negative prognostic factor, as it may prevent proper melanoma thickness measurement. There is no consensus regarding the need for sentinel lymph node biopsy (SLNB) when regression is present within the primary tumour. What does this study add? Regression alone should not be a reason to perform SLNB in thin melanoma. Regression can be considered a favourable prognostic factor for overall survival and disease-free survival in patients with AJCC stage I-II melanoma.

Original languageEnglish
Pages (from-to)1240-1245
Number of pages6
JournalBritish Journal of Dermatology
Volume169
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Neoplasms
Disease-Free Survival
Survival
Neoplasm Staging
Proportional Hazards Models
Lymph Nodes
Neoplasm Metastasis

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Ribero, S., Osella-Abate, S., Sanlorenzo, M., Savoia, P., Astrua, C., Cavaliere, G., ... Quaglino, P. (2013). Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. British Journal of Dermatology, 169(6), 1240-1245. https://doi.org/10.1111/bjd.12586

Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. / Ribero, S.; Osella-Abate, S.; Sanlorenzo, M.; Savoia, P.; Astrua, C.; Cavaliere, G.; Tomasini, C.; Senetta, R.; Macripò, G.; Bernengo, M. G.; Quaglino, P.

In: British Journal of Dermatology, Vol. 169, No. 6, 2013, p. 1240-1245.

Research output: Contribution to journalArticle

Ribero, S, Osella-Abate, S, Sanlorenzo, M, Savoia, P, Astrua, C, Cavaliere, G, Tomasini, C, Senetta, R, Macripò, G, Bernengo, MG & Quaglino, P 2013, 'Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients', British Journal of Dermatology, vol. 169, no. 6, pp. 1240-1245. https://doi.org/10.1111/bjd.12586
Ribero S, Osella-Abate S, Sanlorenzo M, Savoia P, Astrua C, Cavaliere G et al. Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. British Journal of Dermatology. 2013;169(6):1240-1245. https://doi.org/10.1111/bjd.12586
Ribero, S. ; Osella-Abate, S. ; Sanlorenzo, M. ; Savoia, P. ; Astrua, C. ; Cavaliere, G. ; Tomasini, C. ; Senetta, R. ; Macripò, G. ; Bernengo, M. G. ; Quaglino, P. / Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. In: British Journal of Dermatology. 2013 ; Vol. 169, No. 6. pp. 1240-1245.
@article{8f24892d332e429ebdbd121e726c6641,
title = "Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients",
abstract = "Background The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma <1 mm. Objectives To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease-free survival (DFS) and overall survival (OS) in our series. Methods We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I-II melanoma. Results Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression in the primary. Using the Cox multivariate model, histological regression maintained a significant protective role [hazard ratio (HR) 0·62, P = 0·012 for DFS; HR 0·43, P = 0·008 for OS] when corrected for the principal histopathological and clinical features, despite SLNB. Conclusions We confirmed that regression alone should not be a reason to perform SLNB in thin melanoma and, on the contrary, it can be considered a favourable prognostic factor in patients with AJCC stage I-II melanoma. What's already known about this topic? Regression has been considered a negative prognostic factor, as it may prevent proper melanoma thickness measurement. There is no consensus regarding the need for sentinel lymph node biopsy (SLNB) when regression is present within the primary tumour. What does this study add? Regression alone should not be a reason to perform SLNB in thin melanoma. Regression can be considered a favourable prognostic factor for overall survival and disease-free survival in patients with AJCC stage I-II melanoma.",
author = "S. Ribero and S. Osella-Abate and M. Sanlorenzo and P. Savoia and C. Astrua and G. Cavaliere and C. Tomasini and R. Senetta and G. Macrip{\`o} and Bernengo, {M. G.} and P. Quaglino",
year = "2013",
doi = "10.1111/bjd.12586",
language = "English",
volume = "169",
pages = "1240--1245",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients

AU - Ribero, S.

AU - Osella-Abate, S.

AU - Sanlorenzo, M.

AU - Savoia, P.

AU - Astrua, C.

AU - Cavaliere, G.

AU - Tomasini, C.

AU - Senetta, R.

AU - Macripò, G.

AU - Bernengo, M. G.

AU - Quaglino, P.

PY - 2013

Y1 - 2013

N2 - Background The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma <1 mm. Objectives To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease-free survival (DFS) and overall survival (OS) in our series. Methods We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I-II melanoma. Results Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression in the primary. Using the Cox multivariate model, histological regression maintained a significant protective role [hazard ratio (HR) 0·62, P = 0·012 for DFS; HR 0·43, P = 0·008 for OS] when corrected for the principal histopathological and clinical features, despite SLNB. Conclusions We confirmed that regression alone should not be a reason to perform SLNB in thin melanoma and, on the contrary, it can be considered a favourable prognostic factor in patients with AJCC stage I-II melanoma. What's already known about this topic? Regression has been considered a negative prognostic factor, as it may prevent proper melanoma thickness measurement. There is no consensus regarding the need for sentinel lymph node biopsy (SLNB) when regression is present within the primary tumour. What does this study add? Regression alone should not be a reason to perform SLNB in thin melanoma. Regression can be considered a favourable prognostic factor for overall survival and disease-free survival in patients with AJCC stage I-II melanoma.

AB - Background The prognostic significance of regression in primary melanoma has been debated over the past few years. Once it was considered to be a negative prognostic factor, as it may have prevented proper melanoma thickness measurement, therefore affecting the staging of the tumours. For this reason, it was considered to be an indication for sentinel lymph node biopsy (SLNB) in melanoma <1 mm. Objectives To ascertain the utility of SLNB in thin melanoma and to clarify the role of regression in disease-free survival (DFS) and overall survival (OS) in our series. Methods We analysed data collected from 1693 consecutive patients with AJCC (American Joint Committee on Cancer) stage I-II melanoma. Results Globally, SLNB was performed in 656 out of 1693 patients. Regression was present in 349 patients and 223 of them were characterized by thin lesions. SLNB was performed in 104 cases of thin melanoma with regression. The majority of regional lymph node metastases were observed in patients who did not undergo SLNB (89 out of 132). Among the remaining 43 'false negative' patients only three showed regression in the primary. Using the Cox multivariate model, histological regression maintained a significant protective role [hazard ratio (HR) 0·62, P = 0·012 for DFS; HR 0·43, P = 0·008 for OS] when corrected for the principal histopathological and clinical features, despite SLNB. Conclusions We confirmed that regression alone should not be a reason to perform SLNB in thin melanoma and, on the contrary, it can be considered a favourable prognostic factor in patients with AJCC stage I-II melanoma. What's already known about this topic? Regression has been considered a negative prognostic factor, as it may prevent proper melanoma thickness measurement. There is no consensus regarding the need for sentinel lymph node biopsy (SLNB) when regression is present within the primary tumour. What does this study add? Regression alone should not be a reason to perform SLNB in thin melanoma. Regression can be considered a favourable prognostic factor for overall survival and disease-free survival in patients with AJCC stage I-II melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84889028850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889028850&partnerID=8YFLogxK

U2 - 10.1111/bjd.12586

DO - 10.1111/bjd.12586

M3 - Article

C2 - 23952011

AN - SCOPUS:84889028850

VL - 169

SP - 1240

EP - 1245

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -